Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brittany Hunter

Clinical Nurse Specialist, Adult Health Benton, KY Clinical Nurse Specialist

NPI 1568740108 CMS profile 11196211

83 Wellness Way Ste 101&201, Benton, KY 42025

Open in the dashboard

General payments

$1,641

104 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brittany Hunter of Benton, KY is reported in the CMS Open Payments database as having received $1,641 across 104 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14 1
2023 General $618 38
2022 General $598 29
2021 General $411 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brittany Hunter
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Brittany Hunter were reported at $14. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Brittany Hunter Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $411 $133 $48–$445 $132
2022 $598 $163 $57–$526 $149
2023 $618 $173 $64–$597 $160
2024 $0 $171 $54–$575 $164
2025 $14 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $634 29 payments
  2. Novo Nordisk Inc $291 30 payments
  3. Lilly USA, LLC $75 5 payments
  4. Amarin Pharma Inc. $68 4 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $62 4 payments
  6. Otsuka America Pharmaceutical, Inc. $60 3 payments
  7. Novartis Pharmaceuticals Corporation $57 3 payments
  8. Amgen Inc. $53 4 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $50 3 payments
  10. GlaxoSmithKline, LLC. $49 3 payments
  11. Other $241 16 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,641 104 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $331 13 payments
  2. VRAYLAR $195 10 payments
  3. Ozempic $164 22 payments
  4. RYBELSUS $164 22 payments
  5. QULIPTA $114 7 payments
  6. Vascepa $68 4 payments
  7. Wegovy $64 4 payments
  8. Kerendia $50 3 payments
  9. JARDIANCE $50 3 payments
  10. Dayvigo $43 3 payments
  11. Other $663 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 84 drugs

Part D claims

2,836

Median for Nurse Practitioner: 389

Drug cost

$202,577

Median for Nurse Practitioner: $21,885

Branded share of claims

20.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 31 $37,237
Eliquis Apixaban Brand 36 $36,981
Ozempic Semaglutide Brand 21 $29,246
Mounjaro Tirzepatide Brand 27 $28,004
Jardiance Empagliflozin Brand 22 $20,024
Trulicity Dulaglutide Brand 11 $17,533
Trintellix Vortioxetine Hydrobromide Brand 12 $5,753
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 89 $2,148
Gabapentin Generic 112 $1,503
Albuterol Sulfate Hfa Albuterol Sulfate Brand 42 $1,407

The 10 drugs with the highest cost, of 84 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$38,929

Of which drugs: $4,738

Medicare patients

269

Average age 72

Services billed

1,161

147 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 43%
Diabetes 30%
Chronic kidney disease 28%
COPD 26%
Depression 25%
Ischemic heart disease 24%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 19 19 $1,555
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 32 350 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record